BiotechTube

Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Vehicle Proprietary Ophthalmic Solution

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Presbyopia

Conditions

Presbyopia, Refractive Errors, Eye Diseases

Trial Timeline

May 5, 2022 → Sep 10, 2022

NCT ID
NCT05294328

About Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Vehicle Proprietary Ophthalmic Solution

Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Vehicle Proprietary Ophthalmic Solution is a phase 2 stage product being developed by LENZ Therapeutics for Presbyopia. The current trial status is completed. This product is registered under clinical trial identifier NCT05294328. Target conditions include Presbyopia, Refractive Errors, Eye Diseases.

What happened to similar drugs?

1 of 6 similar drugs in Presbyopia were approved

Approved (1) Terminated (1) Active (5)
✅AGN-190584AbbVieApproved
🔄AGN-190584 + VehicleAbbViePhase 3
🔄Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Placebo (Vehicle) ophthalmic solutionLENZ TherapeuticsPhase 3
🔄Aceclidine+Brimonidine combination ophthalmic solution + Placebo + Aceclidine Ophthalmic SolutionLENZ TherapeuticsPhase 3
🔄Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + VehicleLENZ TherapeuticsPhase 3
🔄Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + BrimonidineLENZ TherapeuticsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT05431543Phase 2Completed
NCT05294328Phase 2Completed

Competing Products

14 competing products in Presbyopia

See all competitors
ProductCompanyStageHype Score
AGN-241622 + VehicleAbbViePhase 1/2
24
AGN-190584AbbVieApproved
35
AGN-190584 + VehicleAbbViePhase 3
40
UNR844 + PlaceboNovartisPhase 2
27
UNR844-Cl + PlaceboNovartisPhase 2
35
Pilocarpine Ophthalmic Topical Cream, Dose 1 + Pilocarpine Ophthalmic Topical Cream, Dose 2 + Pilocarpine Ophthalmic Topical Cream, Dose 3 + Placebo Ophthalmic Topical CreamGlaukosPhase 2
32
Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Placebo (Vehicle) ophthalmic solutionLENZ TherapeuticsPhase 3
30
Aceclidine+Brimonidine combination ophthalmic solution + Placebo + Aceclidine Ophthalmic SolutionLENZ TherapeuticsPhase 3
30
PRX-100 + PlaceboLENZ TherapeuticsPhase 2
25
Aceclidine+tropicamide combination + Aceclidine + VehicleLENZ TherapeuticsPhase 2
25
LNZ101 (Aceclidine /Brimonidine) ophthalmic solution + LNZ100 (Aceclidine) ophthalmic solution + Placebo (Vehicle) ophthalmic solutionLENZ TherapeuticsPhase 1
19
Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + VehicleLENZ TherapeuticsPhase 3
30
Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Vehicle proprietary ophthalmic solutionLENZ TherapeuticsPhase 2
25
Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + BrimonidineLENZ TherapeuticsPhase 3
30